Cellular and molecular signaling in pathogenic alpha-synuclein neurodegeneration

$60,588P50FY2019NSNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Paper 39576856 Paper 39528671 Paper 38701790 Paper 38182665 Paper 38071218 Paper 37546928 Paper 37388914 Paper 36378485 Paper 36280265 Paper 35654037 Paper 35412917 Paper 35172141 Paper 34759048 Paper 34728675 Paper 34644545 Paper 34355669 Paper 33902708 Paper 33855307 Paper 33749710 Paper 33455856 Paper 33177178 Paper 33147468 Paper 32846140 Paper 32793944 Paper 32736085 Paper 32614981 Paper 32182160 Paper 32138754 Paper 31327044 Paper 31255487 Paper 31250621 Paper 31237944 Paper 31136698 Paper 31131421 Paper 30983154 Paper 30953760 Paper 30798004 Paper 30578620 Paper 30528841 Paper 30448004 Paper 30385548 Paper 30250265 Paper 30220890 Paper 30160596 Paper 30146185 Paper 30111645 Paper 29988049 Paper 29946230 Paper 29897434 Paper 29892066 Paper 29756003 Paper 29703245 Paper 29610302 Paper 29609901 Paper 29478836 Paper 29386392 Paper 29337114 Paper 29311330 Paper 29310663 Paper 29263008 Paper 29198499 Paper 29103051 Paper 28860335 Paper 28674991 Paper 28644039 Paper 28636593 Paper 28509347 Paper 28445716 Paper 28438176 Paper 28383562 Paper 28353284 Paper 28321439 Paper 28213892 Paper 28122242 Paper 28099414 Paper 28061689 Paper 27807026 Paper 27779468 Paper 27733275 Paper 27720485 Paper 27708076 Paper 27693194 Paper 27617269 Paper 27571329 Paper 27476966 Paper 27348587 Paper 27312774 Paper 27273569 Paper 27241037 Paper 26899799 Paper 26808467 Paper 26629917 Paper 26490328 Paper 26442452 Paper 26296077 Paper 26162776 Paper 25663231 Paper 25650144 Paper 25483009 Paper 25349190

Abstract

PROJECT SUMMARY ? Project 3 Parkinson?s disease (PD) is a progressive neurodegenerative disorder characterized by aggregation of the ?- synuclein (?-syn) protein into intracellular inclusions called Lewy bodies (LB) and Lewy neurites (LN). PD presents with both motor and non-motor symptoms. Loss of substantia nigra pars compacta dopamine (DA) neurons and dystrophic striatal projections account for the motor symptoms of PD including a rest tremor, slowness of movement, rigidity, and postural instability. Other neuronal systems affected by pathologic ?-syn contribute to the non-motor symptoms of PD including anxiety, depression, sleep disorders, autonomic dysfunction, constipation, and cognitive impairment. We have compelling evidence that parthanatos contributes to loss of substantia nigra pars compacta DA neurons. However, what role it may play in the general global neurodegeneration suffered in PD has yet to be determined. Together the investigators in this program have developed a new model of ?-synucleinopathy that mimics the stereotypical spread of pathologic ?-syn in the human condition of PD. In the new gut-brain model we will evaluate roles for the c-Abl substrate AIMP2, its activation of PARP1 and parthanatos and the role of the nuclease MIF in the gut peripheral nervous system and in synaptically connected central nervous system regions that contribute to both the motor and non-motor symptoms of PD. Through serum LCAM1+ exosome analysis we will evaluate the utility of phospho- AIMP2 and PAR as disease biomarkers and possible theragnostic markers. Using single nuclei sequencing in the mouse gut-brain model of PD and in PD postmortem tissue coupled with advanced bioinformatic analysis we will explore new signaling networks important in neural dysfunction and degeneration. This investigation will broaden our understanding of the pathogenicity of misfolded ?-syn and will hopefully lead to a new therapeutic intervention for PD. Additionally, this work will provide a new animal model of ?-syn transmission that can be used for testing the effect of a variety of disease-modifying therapeutics

View original record on NIH RePORTER →